Sarepta Therapeutics Boston Consulting Group Matrix
Actionable Strategy Starts Here
Sarepta’s BCG Matrix snapshot shows which therapies are sprinting ahead and which need a rethink — a quick, honest look at Stars, Cash Cows, Dogs, and Question Marks in a high-stakes biotech market. This preview teases the patterns; the full BCG Matrix gives quadrant-by-quadrant evidence, strategic recommendations, and ready-to-use Word and Excel files. Purchase the complete report to cut through the noise and make confident, capital-allocation decisions now.
Stars
ELEVIDYS (DMD gene therapy)
ELEVIDYS, the first FDA‑approved gene therapy for Duchenne muscular dystrophy (approval 2021), is Sarepta’s lead asset in a gene therapy market growing at double‑digit annual rates; DMD affects roughly 1 in 3,500–5,000 male births, creating a focused patient pool. The program drives prescriber interest and payer dialogue but requires continued investment in manufacturing scale, label expansion, and real‑world evidence generation. Hold the share: with scaled production and broader indications, ELEVIDYS can pivot into a substantial cash engine.
DMD leadership position
Commanding presence across DMD centers and KOL networks gives Sarepta a de facto leadership in a market with an estimated 9,000–12,000 diagnosed US patients (2024) and ~7–9% CAGR growth; brand gravity accelerates trial recruitment, guides guideline influence, and shortens adoption cycles. Defending the moat requires sustained medical education, field strength, and lifecycle programs to compound growth.
AAV manufacturing & platform know‑how
Hard-won AAV process, QC and supply know-how positions Sarepta as a category leader in 2024, differentiating its franchise as demand for gene therapies surges. Ongoing capacity build-out is cash-intensive today but directly underpins clinical and commercial velocity. Rising utilization will markedly improve unit economics and margins. The AAV platform is a strategic asset that anchors long-term growth.
Payer access momentum in rare disease
High-cost, one-time rare-disease therapies require heavy payer-access work but create a flywheel: each positive coverage decision reduces friction for subsequent approvals; Zolgensma launched at $2.125M illustrates the million-dollar pricing backdrop. Outcomes-data generation remains resource-intensive, driving near-term spend for long-term leverage.
- Access intensity: high
- Pricing context: $2.125M benchmark
- Strategy: near-term spend, long-term coverage gains
Clinical data flywheel (DMD)
Expanding datasets, patient registries and real-world evidence in DMD (prevalence ~1 in 3,500–5,000 male births) reinforce Sarepta’s leadership by accelerating label expansions and payer confidence. Robust data drives prescriber comfort and supports premium pricing (exon-skipping products ~300,000 USD/year; single-dose gene therapies exceed 2 million USD), but curation is costly. The compounding, proprietary data moat is hard to replicate.
- Datasets → label & payer leverage
- RWE → prescriber adoption
- High maintenance costs
- Durable competitive moat
Gene therapy leader: 9,000–12,000 US DMD market, single‑dose pricing ~$2.125M
ELEVIDYS (FDA 2021) anchors Sarepta’s Star: leadership in a 9,000–12,000 US DMD patient market (2024) with double‑digit gene‑therapy growth; high upfront R&D and manufacturing spend compress near‑term margins but scale drives margin expansion and pricing power (single‑dose benchmarks >$2M).
| Metric | 2024 value |
|---|---|
| Diagnosed US DMD | 9,000–12,000 |
| ELEVIDYS approval | 2021 |
| Gene therapy price benchmark | $2.125M |
What is included in the product
Detailed Word Document
In-depth BCG Matrix of Sarepta’s portfolio: identifies Stars, Cash Cows, Question Marks and Dogs with clear invest, hold or divest guidance.
Customizable Excel Spreadsheet
One-page BCG view placing Sarepta Therapeutics units in quadrants to ease strategic decisions
Cash Cows
Exondys 51 (eteplirsen)
Exondys 51 (eteplirsen), approved in 2016 as the first exon‑51 skipping therapy for DMD, retains entrenched use in the ~13% of DMD patients amenable to exon 51 skipping. Mature demand and a stable prescriber base keep incremental promo needs low; with an approximate list price near $300,000/year, it delivers solid margins and reliable cash to fund next‑wave programs.
Vyondys 53 (golodirsen)
Vyondys 53 (golodirsen), approved in 2019, serves the roughly 8% of Duchenne patients amenable to exon 53 skipping. By 2024 it showed predictable volumes and reimbursement patterns across major markets. Growth is limited, but manufacturing and distribution remain efficient and low-cost to support. It continues as a steady contributor to Sarepta’s operating cash flow.
Amondys 45 (casimersen)
Amondys 45 (casimersen) was FDA‑approved on February 25, 2021 for DMD amenable to exon 45 skipping, a mutation present in roughly 8% of DMD patients. As a later RNA‑entry therapy it targets a consistent patient pool; growth is modest but profitability benefits from shared commercial infrastructure and field synergies. Its smaller but steady revenues help underwrite Sarepta’s high‑risk R&D pipeline.
U.S. DMD commercial infrastructure
U.S. DMD commercial infrastructure underpins Sarepta as a cash cow: seasoned market access, robust patient services and a national distribution network now optimized for scale with lower incremental costs, keeping churn low and adherence high; serves an estimated 15,000–20,000 US DMD patients (2024) and quietly throws off dependable cash.
- Market access: national payer relationships
- Patient services: care coordination, adherence support
- Distribution: centralized logistics, lower incremental cost
- Scale impact: steady recurring revenue, low churn
Lifecycle & label maintenance revenues
Lifecycle and label-maintenance revenues from Sarepta's approved exon-skipping and gene-targeted therapies deliver steady, incremental indications and age-range expansions that lift persistence with minimal new launch spend, creating a high-margin tail as DMD markets mature and providing ballast in volatile biotech cycles.
- Incremental indications: label expansions
- Age-range use: broader pediatric/adolescent uptake
- Persistence lift: longer treatment duration
- Low incremental spend vs early launches
- High-margin tail, stabilizes revenue volatility
Exon-targeted DMD therapies cover ~29% of patients; US pool 15,000–20,000; price ~300,000/yr
Exondys 51 (2016), Vyondys 53 (2019) and Amondys 45 (2021) serve ~13%, ~8% and ~8% of DMD patients respectively, with Exondys list price ~300,000/year. US DMD pool est. 15,000–20,000 (2024), mature access and patient services keep promo costs low and margins high, providing dependable cash to fund R&D.
| Therapy | Approval | Patient % | List price (yr) |
|---|---|---|---|
| Exondys 51 | 2016 | ~13% | ~300,000 |
| Vyondys 53 | 2019 | ~8% | — |
| Amondys 45 | 2021 | ~8% | — |
Preview = Final Product
Sarepta Therapeutics BCG Matrix
The file you’re previewing is the final Sarepta Therapeutics BCG Matrix you’ll receive after purchase. No watermarks or demo text—just a fully formatted, analysis-ready report tailored to Sarepta’s portfolio. It’s crafted for strategic clarity and immediate use in presentations or planning. Buy once, download instantly, edit or print as needed.
Actionable Strategy Starts Here
Sarepta’s BCG Matrix snapshot shows which therapies are sprinting ahead and which need a rethink — a quick, honest look at Stars, Cash Cows, Dogs, and Question Marks in a high-stakes biotech market. This preview teases the patterns; the full BCG Matrix gives quadrant-by-quadrant evidence, strategic recommendations, and ready-to-use Word and Excel files. Purchase the complete report to cut through the noise and make confident, capital-allocation decisions now.
Stars
ELEVIDYS (DMD gene therapy)
ELEVIDYS, the first FDA‑approved gene therapy for Duchenne muscular dystrophy (approval 2021), is Sarepta’s lead asset in a gene therapy market growing at double‑digit annual rates; DMD affects roughly 1 in 3,500–5,000 male births, creating a focused patient pool. The program drives prescriber interest and payer dialogue but requires continued investment in manufacturing scale, label expansion, and real‑world evidence generation. Hold the share: with scaled production and broader indications, ELEVIDYS can pivot into a substantial cash engine.
DMD leadership position
Commanding presence across DMD centers and KOL networks gives Sarepta a de facto leadership in a market with an estimated 9,000–12,000 diagnosed US patients (2024) and ~7–9% CAGR growth; brand gravity accelerates trial recruitment, guides guideline influence, and shortens adoption cycles. Defending the moat requires sustained medical education, field strength, and lifecycle programs to compound growth.
AAV manufacturing & platform know‑how
Hard-won AAV process, QC and supply know-how positions Sarepta as a category leader in 2024, differentiating its franchise as demand for gene therapies surges. Ongoing capacity build-out is cash-intensive today but directly underpins clinical and commercial velocity. Rising utilization will markedly improve unit economics and margins. The AAV platform is a strategic asset that anchors long-term growth.
Payer access momentum in rare disease
High-cost, one-time rare-disease therapies require heavy payer-access work but create a flywheel: each positive coverage decision reduces friction for subsequent approvals; Zolgensma launched at $2.125M illustrates the million-dollar pricing backdrop. Outcomes-data generation remains resource-intensive, driving near-term spend for long-term leverage.
- Access intensity: high
- Pricing context: $2.125M benchmark
- Strategy: near-term spend, long-term coverage gains
Clinical data flywheel (DMD)
Expanding datasets, patient registries and real-world evidence in DMD (prevalence ~1 in 3,500–5,000 male births) reinforce Sarepta’s leadership by accelerating label expansions and payer confidence. Robust data drives prescriber comfort and supports premium pricing (exon-skipping products ~300,000 USD/year; single-dose gene therapies exceed 2 million USD), but curation is costly. The compounding, proprietary data moat is hard to replicate.
- Datasets → label & payer leverage
- RWE → prescriber adoption
- High maintenance costs
- Durable competitive moat
Gene therapy leader: 9,000–12,000 US DMD market, single‑dose pricing ~$2.125M
ELEVIDYS (FDA 2021) anchors Sarepta’s Star: leadership in a 9,000–12,000 US DMD patient market (2024) with double‑digit gene‑therapy growth; high upfront R&D and manufacturing spend compress near‑term margins but scale drives margin expansion and pricing power (single‑dose benchmarks >$2M).
| Metric | 2024 value |
|---|---|
| Diagnosed US DMD | 9,000–12,000 |
| ELEVIDYS approval | 2021 |
| Gene therapy price benchmark | $2.125M |
What is included in the product
Detailed Word Document
In-depth BCG Matrix of Sarepta’s portfolio: identifies Stars, Cash Cows, Question Marks and Dogs with clear invest, hold or divest guidance.
Customizable Excel Spreadsheet
One-page BCG view placing Sarepta Therapeutics units in quadrants to ease strategic decisions
Cash Cows
Exondys 51 (eteplirsen)
Exondys 51 (eteplirsen), approved in 2016 as the first exon‑51 skipping therapy for DMD, retains entrenched use in the ~13% of DMD patients amenable to exon 51 skipping. Mature demand and a stable prescriber base keep incremental promo needs low; with an approximate list price near $300,000/year, it delivers solid margins and reliable cash to fund next‑wave programs.
Vyondys 53 (golodirsen)
Vyondys 53 (golodirsen), approved in 2019, serves the roughly 8% of Duchenne patients amenable to exon 53 skipping. By 2024 it showed predictable volumes and reimbursement patterns across major markets. Growth is limited, but manufacturing and distribution remain efficient and low-cost to support. It continues as a steady contributor to Sarepta’s operating cash flow.
Amondys 45 (casimersen)
Amondys 45 (casimersen) was FDA‑approved on February 25, 2021 for DMD amenable to exon 45 skipping, a mutation present in roughly 8% of DMD patients. As a later RNA‑entry therapy it targets a consistent patient pool; growth is modest but profitability benefits from shared commercial infrastructure and field synergies. Its smaller but steady revenues help underwrite Sarepta’s high‑risk R&D pipeline.
U.S. DMD commercial infrastructure
U.S. DMD commercial infrastructure underpins Sarepta as a cash cow: seasoned market access, robust patient services and a national distribution network now optimized for scale with lower incremental costs, keeping churn low and adherence high; serves an estimated 15,000–20,000 US DMD patients (2024) and quietly throws off dependable cash.
- Market access: national payer relationships
- Patient services: care coordination, adherence support
- Distribution: centralized logistics, lower incremental cost
- Scale impact: steady recurring revenue, low churn
Lifecycle & label maintenance revenues
Lifecycle and label-maintenance revenues from Sarepta's approved exon-skipping and gene-targeted therapies deliver steady, incremental indications and age-range expansions that lift persistence with minimal new launch spend, creating a high-margin tail as DMD markets mature and providing ballast in volatile biotech cycles.
- Incremental indications: label expansions
- Age-range use: broader pediatric/adolescent uptake
- Persistence lift: longer treatment duration
- Low incremental spend vs early launches
- High-margin tail, stabilizes revenue volatility
Exon-targeted DMD therapies cover ~29% of patients; US pool 15,000–20,000; price ~300,000/yr
Exondys 51 (2016), Vyondys 53 (2019) and Amondys 45 (2021) serve ~13%, ~8% and ~8% of DMD patients respectively, with Exondys list price ~300,000/year. US DMD pool est. 15,000–20,000 (2024), mature access and patient services keep promo costs low and margins high, providing dependable cash to fund R&D.
| Therapy | Approval | Patient % | List price (yr) |
|---|---|---|---|
| Exondys 51 | 2016 | ~13% | ~300,000 |
| Vyondys 53 | 2019 | ~8% | — |
| Amondys 45 | 2021 | ~8% | — |
Preview = Final Product
Sarepta Therapeutics BCG Matrix
The file you’re previewing is the final Sarepta Therapeutics BCG Matrix you’ll receive after purchase. No watermarks or demo text—just a fully formatted, analysis-ready report tailored to Sarepta’s portfolio. It’s crafted for strategic clarity and immediate use in presentations or planning. Buy once, download instantly, edit or print as needed.
Description
Actionable Strategy Starts Here
Sarepta’s BCG Matrix snapshot shows which therapies are sprinting ahead and which need a rethink — a quick, honest look at Stars, Cash Cows, Dogs, and Question Marks in a high-stakes biotech market. This preview teases the patterns; the full BCG Matrix gives quadrant-by-quadrant evidence, strategic recommendations, and ready-to-use Word and Excel files. Purchase the complete report to cut through the noise and make confident, capital-allocation decisions now.
Stars
ELEVIDYS (DMD gene therapy)
ELEVIDYS, the first FDA‑approved gene therapy for Duchenne muscular dystrophy (approval 2021), is Sarepta’s lead asset in a gene therapy market growing at double‑digit annual rates; DMD affects roughly 1 in 3,500–5,000 male births, creating a focused patient pool. The program drives prescriber interest and payer dialogue but requires continued investment in manufacturing scale, label expansion, and real‑world evidence generation. Hold the share: with scaled production and broader indications, ELEVIDYS can pivot into a substantial cash engine.
DMD leadership position
Commanding presence across DMD centers and KOL networks gives Sarepta a de facto leadership in a market with an estimated 9,000–12,000 diagnosed US patients (2024) and ~7–9% CAGR growth; brand gravity accelerates trial recruitment, guides guideline influence, and shortens adoption cycles. Defending the moat requires sustained medical education, field strength, and lifecycle programs to compound growth.
AAV manufacturing & platform know‑how
Hard-won AAV process, QC and supply know-how positions Sarepta as a category leader in 2024, differentiating its franchise as demand for gene therapies surges. Ongoing capacity build-out is cash-intensive today but directly underpins clinical and commercial velocity. Rising utilization will markedly improve unit economics and margins. The AAV platform is a strategic asset that anchors long-term growth.
Payer access momentum in rare disease
High-cost, one-time rare-disease therapies require heavy payer-access work but create a flywheel: each positive coverage decision reduces friction for subsequent approvals; Zolgensma launched at $2.125M illustrates the million-dollar pricing backdrop. Outcomes-data generation remains resource-intensive, driving near-term spend for long-term leverage.
- Access intensity: high
- Pricing context: $2.125M benchmark
- Strategy: near-term spend, long-term coverage gains
Clinical data flywheel (DMD)
Expanding datasets, patient registries and real-world evidence in DMD (prevalence ~1 in 3,500–5,000 male births) reinforce Sarepta’s leadership by accelerating label expansions and payer confidence. Robust data drives prescriber comfort and supports premium pricing (exon-skipping products ~300,000 USD/year; single-dose gene therapies exceed 2 million USD), but curation is costly. The compounding, proprietary data moat is hard to replicate.
- Datasets → label & payer leverage
- RWE → prescriber adoption
- High maintenance costs
- Durable competitive moat
Gene therapy leader: 9,000–12,000 US DMD market, single‑dose pricing ~$2.125M
ELEVIDYS (FDA 2021) anchors Sarepta’s Star: leadership in a 9,000–12,000 US DMD patient market (2024) with double‑digit gene‑therapy growth; high upfront R&D and manufacturing spend compress near‑term margins but scale drives margin expansion and pricing power (single‑dose benchmarks >$2M).
| Metric | 2024 value |
|---|---|
| Diagnosed US DMD | 9,000–12,000 |
| ELEVIDYS approval | 2021 |
| Gene therapy price benchmark | $2.125M |
What is included in the product
Detailed Word Document
In-depth BCG Matrix of Sarepta’s portfolio: identifies Stars, Cash Cows, Question Marks and Dogs with clear invest, hold or divest guidance.
Customizable Excel Spreadsheet
One-page BCG view placing Sarepta Therapeutics units in quadrants to ease strategic decisions
Cash Cows
Exondys 51 (eteplirsen)
Exondys 51 (eteplirsen), approved in 2016 as the first exon‑51 skipping therapy for DMD, retains entrenched use in the ~13% of DMD patients amenable to exon 51 skipping. Mature demand and a stable prescriber base keep incremental promo needs low; with an approximate list price near $300,000/year, it delivers solid margins and reliable cash to fund next‑wave programs.
Vyondys 53 (golodirsen)
Vyondys 53 (golodirsen), approved in 2019, serves the roughly 8% of Duchenne patients amenable to exon 53 skipping. By 2024 it showed predictable volumes and reimbursement patterns across major markets. Growth is limited, but manufacturing and distribution remain efficient and low-cost to support. It continues as a steady contributor to Sarepta’s operating cash flow.
Amondys 45 (casimersen)
Amondys 45 (casimersen) was FDA‑approved on February 25, 2021 for DMD amenable to exon 45 skipping, a mutation present in roughly 8% of DMD patients. As a later RNA‑entry therapy it targets a consistent patient pool; growth is modest but profitability benefits from shared commercial infrastructure and field synergies. Its smaller but steady revenues help underwrite Sarepta’s high‑risk R&D pipeline.
U.S. DMD commercial infrastructure
U.S. DMD commercial infrastructure underpins Sarepta as a cash cow: seasoned market access, robust patient services and a national distribution network now optimized for scale with lower incremental costs, keeping churn low and adherence high; serves an estimated 15,000–20,000 US DMD patients (2024) and quietly throws off dependable cash.
- Market access: national payer relationships
- Patient services: care coordination, adherence support
- Distribution: centralized logistics, lower incremental cost
- Scale impact: steady recurring revenue, low churn
Lifecycle & label maintenance revenues
Lifecycle and label-maintenance revenues from Sarepta's approved exon-skipping and gene-targeted therapies deliver steady, incremental indications and age-range expansions that lift persistence with minimal new launch spend, creating a high-margin tail as DMD markets mature and providing ballast in volatile biotech cycles.
- Incremental indications: label expansions
- Age-range use: broader pediatric/adolescent uptake
- Persistence lift: longer treatment duration
- Low incremental spend vs early launches
- High-margin tail, stabilizes revenue volatility
Exon-targeted DMD therapies cover ~29% of patients; US pool 15,000–20,000; price ~300,000/yr
Exondys 51 (2016), Vyondys 53 (2019) and Amondys 45 (2021) serve ~13%, ~8% and ~8% of DMD patients respectively, with Exondys list price ~300,000/year. US DMD pool est. 15,000–20,000 (2024), mature access and patient services keep promo costs low and margins high, providing dependable cash to fund R&D.
| Therapy | Approval | Patient % | List price (yr) |
|---|---|---|---|
| Exondys 51 | 2016 | ~13% | ~300,000 |
| Vyondys 53 | 2019 | ~8% | — |
| Amondys 45 | 2021 | ~8% | — |
Preview = Final Product
Sarepta Therapeutics BCG Matrix
The file you’re previewing is the final Sarepta Therapeutics BCG Matrix you’ll receive after purchase. No watermarks or demo text—just a fully formatted, analysis-ready report tailored to Sarepta’s portfolio. It’s crafted for strategic clarity and immediate use in presentations or planning. Buy once, download instantly, edit or print as needed.
